| BEMCX | RNWAX | BEMCX / RNWAX | |
| Total Expense Ratio | 2.07 | 1.66 | 125% |
| Annual Report Gross Expense Ratio | 2.07 | 1.66 | 125% |
| Fund Existence | 13 years | 24 years | - |
| Gain YTD | 19.514 | 13.903 | 140% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2500 | 250 | 1,000% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 1.32B | 90.9B | 1% |
| Annual Yield % from dividends | 1.31 | 0.49 | 269% |
| Returns for 1 year | 45.55 | 20.59 | 221% |
| Returns for 3 years | 92.61 | 46.08 | 201% |
| Returns for 5 years | 66.67 | 9.71 | 687% |
| Returns for 10 years | 129.43 | 112.99 | 115% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FBDIX | 189.03 | N/A | N/A |
| Franklin Biotechnology Discovery A | |||
| POMIX | 77.59 | N/A | N/A |
| T. Rowe Price Total Equity Market Idx | |||
| TPYYX | 8.52 | N/A | N/A |
| Touchstone Sands Capital Intl Gr Eq Y | |||
| VWNDX | 23.48 | N/A | N/A |
| Vanguard Windsor Investor Shares | |||
| FACSX | 57.32 | N/A | N/A |
| Nuveen Mid Cap Value Opportunities C | |||